Research progress on nanobodies in the diagnosis and treatment of natural toxin poisoning
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Toxin Mechanisms and Immunotoxins · Monoclonal and Polyclonal Antibodies Research · Biochemical and Structural Characterization
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Drug development using natural toxins10.3390/toxins13060414 ↗
2. Botulinum toxin as a biological warfare agent: Poisoning, diagnosis and countermeasures10.2174/1389557520666200228105312 ↗
3. Characterization of neutralizing chimeric heavy-chain antibodies against tetanus toxin10.1080/21645515.2024.2366641 ↗
4. A phase 1 study in healthy subjects to evaluate the safety and pharmacokinetics of a human monoclonal antibody (S315) against diphtheria toxin
5. Snake venom components: tools and cures to target cardiovascular diseases10.3390/molecules26082223 ↗
6. Scorpion venom peptides: Molecular diversity, structural characteristics, and therapeutic use from channelopathies to viral infections and cancers10.1016/j.phrs.2023.106978 ↗
7. Marine algal toxins and public health: insights from shellfish and fish, the main biological vectors10.3390/md22110510 ↗
8. Medical countermeasures against ricin intoxication10.3390/toxins15020100 ↗
9. Plants Producing Ribosome-Inactivating Proteins in Traditional Medicine10.3390/molecules21111560 ↗
10. Aflatoxin contamination, its impact and management strategies: an updated review10.3390/toxins14050307 ↗
11. Smartphone-based dual-mode aptasensor with bifunctional metal-organic frameworks as signal probes for ochratoxin A detection
12. Near-infrared-driven dual-photoelectrode photoelectrochemical sensing for fumonisin B1: integrating a photon up-conversion bio-photocathode with an enhanced light-capturing photoanode10.1016/j.talanta.2024.127047 ↗
13. Nanobodies as novel therapeutic agents in envenomation10.1016/j.bbagen.2018.08.019 ↗
14. Rational designing of an antidote nanoparticle decorated with abiotic polymer ligands for capturing and neutralizing target toxins10.1016/j.jconrel.2017.10.028 ↗
15. Biosynthetic oligoclonal antivenom (Boa) for snakebite and next-generation treatments for snakebite victims10.3390/toxins10120534 ↗
16. Electrochemical methods for evaluation of therapeutic monoclonal antibodies: a review
17. Rationally designed synthetic haptens to generate anti-ciguatoxin monoclonal antibodies, and development of a practical sandwich ELISA to detect ciguatoxins10.3390/toxins11090533 ↗
18. R. Chen, J. Wang, Z. Liu, Preliminary establishment of an electrochemiluminescence immunoassay method for detection of influenza virus B, Sheng Wu Yi Xue Gong Cheng Xue Za. 30 (2013) 968-971.
19. Advancement in COVID-19 detection using nanomaterial-based biosensors10.1002/EXP.20210232 ↗
20. Monoclonal antibodies: a review of therapeutic applications and future prospects10.4314/tjpr.v16i3.29 ↗
21. The therapeutic potential of nanobodies10.1007/s40259-019-00392-z ↗
22. A novel nanobody broadly neutralizes SARS-CoV-2 via induction of spike trimer dimers conformation10.1002/EXP.20230086 ↗
23. Nanobodies in human infections: prevention, detection, and treatment10.1080/08820139.2019.1688828 ↗
24. Food-borne biotoxin neutralization in Vivo by nanobodies: current status and prospects10.1021/acs.jafc.4c02257 ↗
25. Hamers-Casterman · Nature · 1993 · 363 · 44610.1038/363446a0 ↗
26. Biosynthetic oligoclonal antivenom (BOA) for snakebite and next-generation treatments for snakebite victims10.3390/toxins10120534 ↗
27. NANOBODIES: a review of diagnostic and therapeutic applications10.3390/ijms24065994 ↗
28. Exploiting nanobodies' singular traits10.1146/annurev-immunol-042617-053327 ↗
29. Nanobody-derived nanobiotechnology tool kits for diverse biomedical and biotechnology applications10.2147/IJN.S107194 ↗
30. Structural insights into the design of synthetic nanobody libraries10.3390/molecules27072198 ↗
31. Applications of nanobodies10.1146/annurev-animal-021419-083831 ↗
32. Nanobodies: natural single-domain antibodies10.1146/annurev-biochem-063011-092449 ↗
33. Camelid immunoglobulins and nanobody technology10.1016/j.vetimm.2008.10.299 ↗
34. Facile discovery of surrogate cytokine agonists10.1016/j.cell.2022.02.025 ↗
35. Applications of nanobodies in plant science and biotechnology10.1007/s11103-020-01082-z ↗
36. Targeted Alpha Therapy (TAT) with single-domain antibodies (Nanobodies)10.3390/cancers15133493 ↗
37. Fusion proteins for half-life extension of biologics as a strategy to make biobetters10.1007/s40259-015-0133-6 ↗
38. Strategies for extended serum half-life of protein therapeutics10.1016/j.copbio.2011.06.012 ↗
39. Clustered nanobody-drug conjugates for targeted cancer therapy10.1039/D0CC03396K ↗
40. Caplacizumab in acquired thrombotic thrombocytopenic purpura: a profile of its use10.1007/s40267-019-00632-w ↗
41. Modular design of nanobody-drug conjugates for targeted-delivery of platinum anticancer drugs with an MRI contrast agent10.1039/C9CC01391A ↗
42. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 201910.1093/annonc/mdx308 ↗
43. Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human10.4161/mabs.23684 ↗
44. Fenobody: a ferritin-displayed nanobody with high apparent affinity and half-life extension10.1021/acs.analchem.7b05217 ↗
45. VHH, bivalent domains and chimeric Heavy chain-only antibodies with high neutralizing efficacy for scorpion toxin AahI'10.1016/j.molimm.2008.04.011 ↗
46. Ricin10.1016/S0041-0101(01)00158-1 ↗
47. Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies10.1016/S0167-4838(99)00030-8 ↗
48. R. Ben Abderrazek, C. Vincke, I. Hmila, D. Saerens, N. Abidi, M. El Ayeb, S. Muyldermans, B. Bouhaouala-Zahar, Protein Engineering, Design Selection 24 (2011) 727-735.10.1093/protein/gzr037 ↗
49. Trends Biotechnol. Development of Cys38 knock-out and humanized version of NbAahII10 nanobody with improved neutralization of AahII scorpion toxin
50. Immunogenicity risk profile of nanobodies10.3389/fimmu.2021.632687 ↗
51. General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold10.1074/jbc.M806889200 ↗
52. Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products10.1016/j.jconrel.2022.09.031 ↗
53. Conjugation of oxaliplatin with PEGylated-nanobody for enhancing tumor targeting and prolonging circulation10.1016/j.jinorgbio.2021.111553 ↗
54. Expression of single-domain antibody in different systems10.1007/s00253-017-8644-3 ↗
55. A comprehensive comparison between camelid nanobodies and single chain variable fragments10.1186/s40364-021-00332-6 ↗
56. Efficient expression of the anti-AahI' scorpion toxin nanobody under a new functional form in a Pichia pastoris system10.1002/bab.67 ↗
57. Camelid-derived heavy-chain nanobody against Clostridium botulinum neurotoxin E in Pichia pastoris10.1002/bab.1226 ↗
58. Botulinum and tetanus neurotoxins10.1146/annurev-biochem-013118-111654 ↗
59. Cure of experimental botulism and antibotulismic effect of toosendanin
60. Therapeutic efficacy of equine botulism antitoxin in Rhesus macaques10.1371/journal.pone.0186892 ↗
61. Human botulism immune globulin for the treatment of infant botulism10.1056/NEJMoa051926 ↗
62. Safety and improved clinical outcomes in patients treated with new equine-derived heptavalent botulinum antitoxin10.1093/cid/cix816 ↗
63. Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases10.1016/j.toxicon.2010.07.003 ↗
64. A V H H that neutralizes the zinc metalloproteinase activity of botulinum neurotoxin type A10.1074/jbc.M109.073163 ↗
65. A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region10.1016/j.jmb.2010.01.070 ↗
66. A camelid single-domain antibody neutralizes botulinum neurotoxin A by blocking host receptor binding10.1038/s41598-017-07457-5 ↗
67. In vivo neutralization of botulinum neurotoxins serotype E with heavy-chain camelid antibodies (VHH)10.1007/s12033-013-9669-1 ↗
68. Camelid-derived heavy-chain nanobody against Clostridium botulinum neurotoxin E in Pichia pastoris10.1002/bab.1226 ↗
69. A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model10.1371/journal.pone.0029941 ↗
70. Structural insights into rational design of single-domain antibody-based antitoxins against botulinum neurotoxins10.1016/j.celrep.2020.01.107 ↗
71. Camelid VHH antibodies that neutralize botulinum neurotoxin serotype E intoxication or protease function10.3390/toxins12100611 ↗
72. Two VHH antibodies neutralize botulinum neurotoxin E1 by blocking its membrane translocation in host cells10.3390/toxins12100616 ↗
73. Two VHH antibodies neutralize botulinum neurotoxin E1 by blocking its membrane translocation in host cells
74. Delivery of single-domain antibodies into neurons using a chimeric toxin-based platform is therapeutic in mouse models of botulism10.1126/scitranslmed.aaz4197 ↗
75. Neuronal delivery of antibodies has therapeutic effects in animal models of botulism10.1126/scitranslmed.abd7789 ↗
76. Single-domain antibody delivery using an mRNA platform protects against lethal doses of botulinum neurotoxin A10.3389/fimmu.2023.1098302 ↗
77. Design and evaluation of mRNA encoding recombinant neutralizing antibodies for botulinum neurotoxin type B intoxication prophylaxis10.1080/21645515.2024.2358570 ↗
78. Snake venom toxins: potential anticancer therapeutics10.1002/jat.4544 ↗
79. Snake venoms, cellular mechanisms of action of snake phospholipase A2
80. Snake antivenom: Challenges and alternate approaches10.1016/j.bcp.2020.114135 ↗
81. Strategy for a globally coordinated response to a priority neglected tropical disease: snakebite envenoming10.1371/journal.pntd.0007059 ↗
82. Engineering of single-domain antibodies for next-generation snakebite antivenoms10.1016/j.ijbiomac.2021.06.043 ↗
83. Therapeutic antibodies: successes, limitations and hopes for the future10.1111/j.1476-5381.2009.00190.x ↗
84. Generation of a cost-effective cell line for support of high-throughput isolation of primary human B cells and monoclonal neutralizing antibodies10.1016/j.jim.2020.112901 ↗
85. Snake bite10.1016/S0140-6736(09)61754-2 ↗
86. In vivo neutralization of α-cobratoxin with high-affinity llama single-domain antibodies (VHHs) and a VHH-Fc antibody10.1371/journal.pone.0069495 ↗
87. In vivo neutralization of α-cobratoxin with high-affinity llama single-domain antibodies (VHHs) and a VHH-Fc antibody10.1371/journal.pone.0069495 ↗
88. Generation of multivalent nanobody-based proteins with improved neutralization of long α-neurotoxins from elapid snakes10.1021/acs.bioconjchem.2c00220 ↗
89. Neutralizing nanobodies against venoms from naja haje species captured in north Africa10.3390/toxins16090393 ↗
90. Cytotoxicity of snake venom enzymatic toxins: phospholipase A2 and l-amino acid oxidase10.1042/BST20200110 ↗
91. Arachnid envenomation10.1016/j.emc.2004.01.006 ↗
92. Crystal structure of crotoxin reveals key residues involved in the stability and toxicity of this potent heterodimeric β-neurotoxin10.1016/j.jmb.2011.07.027 ↗
93. Camelid single-domain antibodies (VHHs) against crotoxin: a basis for developing modular building blocks for the enhancement of treatment or diagnosis of crotalic envenoming10.3390/toxins10040142 ↗
94. Preclinical evaluation of single domain antibody efficacy in mitigating local tissue damage induced by Bothrops snake envenomation10.1016/j.intimp.2024.112215 ↗
95. Snake Venom Metalloproteinases (SVMPs): a structure-function update10.1016/j.toxcx.2020.100052 ↗
96. J Biol Chem, The reprolysin jararhagin, a snake venom metalloproteinase, functions as a fibrillar collagen agonist involved in fibroblast cell adhesion and signaling10.1074/jbc.M202049200 ↗
97. Development of nanobodies against hemorrhagic and myotoxic components of bothrops atrox snake venom10.3389/fimmu.2020.00655 ↗
98. Molecular and functional characterization of a new non-hemorrhagic metalloprotease from Bothrops jararacussu snake venom with antiplatelet activity10.1016/j.peptides.2007.10.010 ↗
99. Anti-metalloprotease P-I single-domain antibodies: tools for next-generation snakebite10.1155/2022/2748962 ↗
100. Scorpion venom: detriments and benefits10.3390/biomedicines8050118 ↗